Advanced Enzyme Technologies Ltd
NSE: ADVENZYMES BSE: 540025
Advanced Enzyme Technologies Limited is engaged in the business of manufacturing and sales of enzymes.[1]
₹360
52W: ₹252 — ₹420
PE 29.9 · Book ₹63.4 · +468% vs bookMarket Cap₹4,035 Cr
Stock P/E29.9Price to Earnings
ROCE24.1%Return on Capital
ROE20.2%Return on Equity
Div. Yield1.44%Face Value ₹2
Strengths
- +Company has reduced debt.
- +Company is almost debt free.
- +Company has been maintaining a healthy dividend payout of 40.4%
Weaknesses
- −The company has delivered a poor sales growth of 9.82% over past five years.
- −Earnings include an other income of Rs.59.5 Cr.
- −Promoter holding has decreased over last 3 years: -6.61%
Shareholding Pattern
Promoters43.26%
FIIs25.5%
DIIs5.41%
Public25.85%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 43.02% | 42.95%▼0.1 | 42.92%▼0.0 | 43.08%▲0.2 | 43.08% | 43.08% | 43.04%▼0.0 | 43.26%▲0.2 |
| FIIs | 12.03% | 12.63%▲0.6 | 12.57%▼0.1 | 11.9%▼0.7 | 23.45%▲11.5 | 25.41%▲2.0 | 25.85%▲0.4 | 25.5%▼0.4 |
| DIIs | 8.08% | 8.02%▼0.1 | 8.17%▲0.2 | 8.19%▲0.0 | 8.45%▲0.3 | 6.41%▼2.0 | 5.51%▼0.9 | 5.41%▼0.1 |
| Public | 36.87% | 36.4%▼0.5 | 36.31%▼0.1 | 36.82%▲0.5 | 25%▼11.8 | 25.09%▲0.1 | 25.62%▲0.5 | 25.85%▲0.2 |
Financial Statements
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 91 | 92 | 86 | 77 | 101 | 87 | 125 | 116 | 96 | 116 |
| Expenses | 67 | 63 | 65 | 64 | 79 | 73 | 94 | 86 | 72 | 90 |
| Operating Profit | 25 | 29 | 21 | 14 | 22 | 14 | 31 | 30 | 23 | 27 |
| OPM % | 27% | 32% | 24% | 17% | 22% | 16% | 24% | 26% | 25% | 23% |
| Net Profit | 19 | 3 | 67 | 9 | 15 | 11 | 74 | 22 | 13 | 22 |
| EPS ₹ | 1.71 | 0.28 | 6 | 0.82 | 1.36 | 0.99 | 6.61 | 1.99 | 1.18 | 1.99 |
AI Insights
Revenue Trend
Mar 2026 revenue at ₹453Cr, up 29.1% YoY. OPM at 24%.
Debt Position
Borrowings at ₹2Cr. Debt-to-equity ratio: 0.00x. Healthy balance sheet.
Capex Cycle
CWIP at ₹49Cr (32% of fixed assets). Significant capex underway — growth runway building.
Institutional Flow
DIIs: 5.41% (-2.17pp change). FIIs: 25.5% (+3.61pp change). Promoters hold 43.26%.
Margin & Efficiency
ROCE improving from 14% (Mar 2015) to 24% (Mar 2026). Working capital days: 190.
Valuation
PE 29.9x with 24.1% ROCE. Price is 468% above book value of ₹63.4. Dividend yield: 1.44%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 2d - The transcript of the earnings call held on May 12, 2026.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 12 May - Audio recording of May 12, 2026 analyst call on audited Q4 and FY26 results uploaded.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 11 May - Copy of newspaper publication of extract of audited consolidated financial results for quarter and year ended March 31, 2026.
- Announcement under Regulation 30 (LODR)-Press Release / Media Release 9 May - Advanced Enzyme announced Q4 FY26 and FY26 results; revenue rose 17%, PAT 30%, call on May 12.
- Announcement under Regulation 30 (LODR)-Investor Presentation 9 May - Earnings Presentation for the Quarter and Year ended March 31, 2026
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Financial Year 2023 from bse